Epidermal growth factor receptor inhibitors: A review of cutaneous adverse events and management

Dermatology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Chanprapaph, K ^a   Vachiramon, V ^a   Rattanakaemakorn, P ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MATUZUMAB; MINOCYCLINE; PANITUMUMAB; TAZAROTENE; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

CLINICAL TRIAL; DISEASE SEVERITY; HAIR GROWTH; HUMAN; MACULOPAPULAR RASH; MUCOSA INFLAMMATION; POSTINFLAMMATORY HYPERPIGMENTATION; PROPHYLAXIS; RASH; REVIEW; SKIN TOXICITY; TOPICAL TREATMENT;

EID: 84897903698     PISSN: None     EISSN: 16876113     Source Type: Journal    
DOI: 10.1155/2014/734249     Document Type: Review

References (50)

1. Ciardiello F., Tortora G., EGFR antagonists in cancer treatment. The New England Journal of Medicine 2008 358 11 1160 1174 2-s2.0-40849147041 10.1056/NEJMra0707704 (Pubitemid 351398490)
2. Harari P. M., Allen G. W., Bonner J. A., Biology of interactions: antiepidermal growth factor receptor agents. Journal of Clinical Oncology 2007 25 26 4057 4065 2-s2.0-34748831698 10.1200/JCO.2007.11.8984 (Pubitemid 47492950)
3. Burtness B., Goldwasser M. A., Flood W., Mattar B., Forastiere A. A., Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. Journal of Clinical Oncology 2005 23 34 8646 8654 2-s2.0-33144461661 10.1200/JCO.2005.02.4646 (Pubitemid 46211507)
4. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. The New England Journal of Medicine 2004 351 4 337 345 2-s2.0-3242720345 10.1056/NEJMoa033025 (Pubitemid 38944402)
5. Fakih M., Vincent M., Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Current Oncology 2010 17 supplement 1 S18 S30
6. Molinari E., de Quatrebarbes J., André T., Aractingi S., Cetuximab-induced acne. Dermatology 2005 211 4 330 333 2-s2.0-27844434729 10.1159/000088502 (Pubitemid 41642106)
7. Hu J. C., Sadeghi P., Pinter-Brown L. C., Yashar S., Chiu M. W., Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. Journal of the American Academy of Dermatology 2007 56 2 317 326 2-s2.0-33846245846 10.1016/j.jaad.2006.09.005 (Pubitemid 46091817)
8. Lacouture M. E., Lai S. E., The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. British Journal of Dermatology 2006 155 4 852 854 2-s2.0-33748466742 10.1111/j.1365-2133.2006.07452.x (Pubitemid 44352579)
9. Belloni B., Schonewolf N., Rozati S., Goldinger S. M., Dummer R., Cutaneous drug eruptions associated with the use of new oncological drugs. Chemical Immunology and Allergy 2012 97 191 202 10.1159/000335632
10. Guttman-Yassky E., Mita A., de Jonge M., Matthews L., McCarthy S., Iwata K. K., Verweij J., Rowinsky E. K., Krueger J. G., Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. European Journal of Cancer 2010 46 11 2010 2019 2-s2.0-77954216241 10.1016/j.ejca.2010.04.028
11. Eilers R. E., Gandhi M., Patel J. D., Mulcahy M. F., Agulnik M., Hensing T., Lacouture M. E., Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. Journal of the National Cancer Institute 2010 102 1 47 53 2-s2.0-74049120784 10.1093/jnci/djp439
12. Kardaun S. H., van Duinen K. F., Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clinical and Experimental Dermatology 2008 33 1 46 49 2-s2.0-37349121157 10.1111/j.1365-2230.2007.02556.x (Pubitemid 350308526)
13. Lord H. K., Junor E., Ironside J., Cetuximab is effective, but more toxic than reported in the Bonner trial. Clinical Oncology 2008 20 1 96 2-s2.0-38149016237 10.1016/j.clon.2007.09.003
14. Jacot W., Bessis D., Jorda E., Ychou M., Fabbro M., Pujol J.-L., Guillot B., Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. British Journal of Dermatology 2004 151 1 238 241 2-s2.0-4043133757 10.1111/j.1365-2133.2004.06026.x (Pubitemid 39061311)
15. Abdullah S. E., Haigentz M. Jr., Piperdi B., Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management. Chemotherapy Research and Practice 2012 2012 10 351210 10.1155/2012/351210
16. Gutzmer R., Wollenberg A., Ugurel S., Homey B., Ganser A., Kapp A., Cutaneous side effects of new antitumor drugs: clinical features and management. Deutsches Ärzteblatt International 2012 109 8 133 140 2-s2.0-84859461604 10.3238/arztebl.2012.0133
17. Chanprapaph K., Pongcharoen P., Vachiramon V., Cutaneous adverse events of epidermal growth factor receptor inhibitors: a review of 99 cases. Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University. In press
18. Osio A., Mateus C., Soria J.-C., Massard C., Malka D., Boige V., Besse B., Robert C., Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. British Journal of Dermatology 2009 161 3 515 521 2-s2.0-69149096621 10.1111/j.1365-2133.2009.09214.x
19. Boucher K. W., Davidson K., Mirakhur B., Goldberg J., Heymann W. R., Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. Journal of the American Academy of Dermatology 2002 47 4 632 633 2-s2.0-0036788811 10.1067/mjd.2002.124621
20. Dainichi T., Tanaka M., Tsuruta N., Furue M., Noda K., Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology 2003 207 3 324 325 2-s2.0-0142258862 10.1159/000073100 (Pubitemid 37329208)
21. Chang G.-C., Yang T.-Y., Chen K.-C., Yin M.-C., Wang R.-C., Lin Y.-C., Complications of therapy in cancer patients: case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2004 22 22 4646 4648 2-s2.0-11944254029 10.1200/JCO.2004.02.168 (Pubitemid 41185134)
22. Chiu H. Y., Chiu H. C., Scalp pustules in a patient receiving chemotherapy. The Journal of the American Medical Association 2013 310 10 1068 1069 10.1001/jama.2013.276214
23. Donovan J. C., Ghazarian D. M., Shaw J. C., Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib. Archives of Dermatology 2008 144 11 1524 1525 2-s2.0-56549097598 10.1001/archderm.144.11. 1524
24. Graves J. E., Jones B. F., Lind A. C., Heffernan M. P., Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. Journal of the American Academy of Dermatology 2006 55 2 349 353 2-s2.0-33745815322 10.1016/j.jaad.2005.12.016 (Pubitemid 44038007)
25. Cheng Y. P., Chen H. J., Chiu H. C., Erlotinib-induced hair repigmentation. International Journal of Dermatology 2014 53 1 e55 e57 10.1111/j.1365-4632.2011.05422.x
26. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. US Department of Health and Human Services. National Institute of Health. National Cancer Institute, 2009, http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-5x7.pdf
27. Pérez-Soler R., Chachoua A., Hammond L. A., Rowinsky E. K., Huberman M., Karp D., Rigas J., Clark G. M., Santabárbara P., Bonomi P., Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Journal of Clinical Oncology 2004 22 16 3238 3247 2-s2.0-4344646459 10.1200/JCO.2004.11.057 (Pubitemid 41103678)
28. Liu H. B., Wu Y., Lv T. F., Yao Y. W., Xiao Y. Y., Yuan D. M., Song Y., Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE 2013 8 1 e55128 10.1371/journal.pone.0055128
29. Perez C. A., Song H., Raez L. E., Agulnik M., Grushko T. A., Dekker A., Stenson K., Blair E. A., Olopade O. I., Seiwert T. Y., Vokes E. E., Cohen E. E. W., Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncology 2012 48 9 887 892 2-s2.0-84859634535 10.1016/j.oraloncology.2012.03.020
30. Bonner J. A., Harari P. M., Giralt J., Azarnia N., Shin D. M., Cohen R. B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M. S., Baselga J., Youssoufian H., Amellal N., Rowinsky E. K., Ang K. K., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 2006 354 6 567 578 2-s2.0-32144433159 10.1056/NEJMoa053422 (Pubitemid 43209104)
31. Bonner J. A., Harari P. M., Giralt J., Cohen R. B., Jones C. U., Sur R. K., Raben D., Baselga J., Spencer S. A., Zhu J., Youssoufian H., Rowinsky E. K., Ang K. K., Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 2010 11 1 21 28 2-s2.0-73249143536 10.1016/S1470-2045(09)70311-0
32. Giro C., Berger B., Bölke E., Ciernik I. F., Duprez F., Locati L., Maillard S., Ozsahin M., Pfeffer R., Robertson A. G., Langendijk J. A., Budach W., High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiotherapy and Oncology 2009 90 2 166 171 2-s2.0-59649123356 10.1016/j.radonc.2008.09.007
33. Tejwani A., Wu S., Jia Y., Agulnik M., Millender L., Lacouture M. E., Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009 115 6 1286 1299 2-s2.0-63449110924 10.1002/cncr.24120
34. Li T., Perez-Soler R., Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted Oncology 2009 4 2 107 119 2-s2.0-67349083594 10.1007/s11523-009-0114-0
35. Scope A., Agero A. L. C., Dusza S. W., Myskowski P. L., Lieb J. A., Saltz L., Kemeny N. E., Halpern A. C., Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. Journal of Clinical Oncology 2007 25 34 5390 5396 2-s2.0-36849093857 10.1200/JCO.2007.12.6987 (Pubitemid 350232214)
36. Jatoi A., Rowland K., Sloan J. A., Gross H. M., Fishkin P. A., Kahanic S. P., Novotny P. J., Schaefer P. L., Johnson D. B., Tschetter L. K., Loprinzi C. L., Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008 113 4 847 853 2-s2.0-50249101750 10.1002/cncr.23621
37. Lacouture M. E., Mitchell E. P., Piperdi B., Pillai M. V., Shearer H., Iannotti N., Xu F., Yassine M., Skin toxicity evaluation protocol with Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2010 28 8 1351 1357 2-s2.0-77950495095 10.1200/JCO.2008.21.7828
38. Deplanque G., Chavaillon J., Vergnenegre A., Falchero L., Fraboulet G., Gervais R., Taviot B., Souquet P. J., Robert C., Chosidow O., CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinibinduced folliculitis in non-small cell lung cancer patients. Journal of Clinical Oncology 2010 28, abstract 9019
39. Ocvirk J., Heeger S., McCloud P., Hofheinz R. D., A review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis. Radiology and Oncology 2013 47 2 166 175 10.2478/raon-2013-0014
40. Scope A., Lieb J. A., Dusza S. W., Phelan D. L., Myskowski P. L., Saltz L., Halpern A. C., A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. Journal of the American Academy of Dermatology 2009 61 4 614 620 2-s2.0-66749140972 10.1016/j.jaad.2009.03.046
41. Ocvirk J., Rebersek M., Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. Journal of Clinical Oncology 2009 27, supplement e15087
42. Jatoi A., Thrower A., Sloan J. A., Flynn P. J., Wentworth-Hartung N. L., Dakhil S. R., Mattar B. I., Nikcevich D. A., Novotny P., Sekulic A., Loprinzi C. L., Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the north central cancer treatment group (N05C4). Oncologist 2010 15 9 1016 1022 2-s2.0-77957818555 10.1634/theoncologist.2010-0082
43. Kanazawa S., Yamaguchi K., Kinoshita Y., Muramatsu M., Komiyama Y., Nomura S., Aspirin reduces adverse effects of gefitinib. Anti-Cancer Drugs 2006 17 4 423 427 2-s2.0-33748185279 10.1097/01.cad.0000203385.45163.76 (Pubitemid 44309985)
44. Wong S., Osann K., Lindgren A., Byun T., Mummaneni M., Pilot cross-over study to evaluate Regenecare topical gel in patients with epidermal growth factor receptor (HER1/EGFR) inhibitors-induced skin toxicity: the final analysis. Journal of Clinical Oncology 2008 26 20507
45. Ocvirk J., Rebersek M., Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème. Radiology and Oncology 2008 42 4 215 224 2-s2.0-58149164701 10.2478/v10019-008-0022-4
46. Pinto C., Barone C., Martoni A., di Tullio P., di Fabio F., Cassano A., Vitamin K1 cream in the management of skin rash during anti-EGFR monocloncal antibody (mAb) treatment in patients with metastatic cancer: first analysis of an observational Italian study. Journal of Clinical Oncology 2011 29, abstract 594
47. Katzer K., Tietze J., Klein E., Heinemann V., Ruzicka T., Wollenberg A., Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab-a report of 29 patients. European Journal of Dermatology 2010 20 1 82 84 2-s2.0-76749117071 10.1684/ejd.2010.0806
48. Pomerantz R. G., Chirinos R. E., Falo L. D. Jr., Geskin L. J., Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Archives of Dermatology 2008 144 7 949 950 2-s2.0-47849098042 10.1001/archderm.144.7.949 (Pubitemid 352039757)
49. Gutzmer R., Werfel T., Mao R., Kapp A., Elsner J., Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. British Journal of Dermatology 2005 153 4 849 851 2-s2.0-26244449709 10.1111/j.1365-2133.2005.06835.x (Pubitemid 41415923)
50. Taguchi K., Fukunaga A., Okuno T., Nishigori C., Successful treatment with adapalene of cetuximab-induced acneiform eruptions. The Journal of Dermatology 2012 39 9 792 794 2-s2.0-83455172816 10.1111/j.1346-8138.2011.01424. x